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CHAPTER 1: BACKGROUND
1.1 Retinal degenerative diseases
Retinal degenerative diseases are caused by progressive death of the photoreceptor
cells, which can lead to vision impairment and even blindness in millions of people. Agerelated macular degeneration (AMD) and retinitis pigmentosa (RP) are two leading retinal
degenerative diseases. AMD often affects people over 50 years of age and leads to a
central field vision loss. The advanced AMD is classified as non-neovascular and
neovascular AMD (Jager, 2008). In the US, approximately 13.4% of people over 60 years
old have AMD (Parmeggiani et al., 2013) and the 15-year cumulative incidence of late
AMD is 8% among AMD patients over 75 years old (Casaroli-Marano et al., 2014). RP is
an inherited ocular disease; more than 2 million people are affected in the world, with a
prevalence of 1 in 3500-5000 people (Anasagasti et al., 2012). More than 65 genes have
been found to be involved in RP (Anasagasti et al., 2012); the onset age of RP patients
can range from infancy to late middle age. Typically, rod photoreceptor cells are first
affected, resulting in night blindness and peripheral vision loss. As the disease progresses,
cone photoreceptor cells are also impaired; consequently patients will have decreased
central vision, visual acuity and day vision. In addition, the retinal pigment epithelium
(RPE) may also get involved (Phelan and Bok, 2000).
At present, there is no cure for retinal degenerative diseases, yet several vision
restoring strategies have been pursued over the past decades. For early stages of retinal
degeneration, when all cell types are still alive, gene replacement therapy is
recommended. If photoreceptors are already degenerated as in late stages, optogenetic
approaches, electronic implants, and stem cell approaches are alternative therapies
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currently under development (Ong and da Cruz, 2012; Sahel and Roska, 2013; Stingl and
Zrenner, 2013).
1.2 Developing therapies
Gene replacement therapy
Gene therapy has been used to potentially treat recessive hereditary diseases that
result from gene mutations in retinal cells. One successful example is the treatment of
Leber Congenital Amaurosis (LCA). LCA is an autosomal recessive eye disease that
affects approximately 1 in 81,000 of the population (Stone, 2007). Mutation of the RPE65
gene comprises 16% of all LCA cases, which are categorized as type 2 LCA (Morimura
et al., 1998). In 2005, Acland et al. restored visual function in LCA dog models by injecting
adeno-associated virus 2 (AAV2) vectors carrying RPE65 cDNA. More excitingly, gene
therapy trials have also been done on RPE65 deficient patients who were reported to
experience a functional improvement in vision (Cideciyan et al., 2008; James W.B.
Bainbridge, 2008). Nevertheless, there are several limitations of gene replacement
therapy. One concern it requires the presence of viable photoreceptor cells (Scholl et al.,
2016). Another concern is that hereditary retinal diseases such as RP are caused by
hundreds of mutated genes, while mutations in 30%-35% of RP patients have not been
identified to date (Petrs-Silva and Linden, 2013). Moreover, the loading vectors such as
AAV, has only a limited capability of ~4.7 kb for transgenes (Sahel and Roska, 2013).
Electronic devices
An electronic method to restore visual function is to put light dependent electric
implants in the eye to stimulate the inner retinal layer, substituting for the light sensory
function of the degenerated photoreceptor layer. The device usually contains an external
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camera and series of stimulating electrodes, and can be fixed epiretinaly, subretinaly, or
suprachoroidaly. However, a major limitation lies in converting the electronic image
received from the camera into effective electrode stimulations and thus neurological
signals. The compatibility of the electrode device and the human eye is another concern
(Stingl and Zrenner, 2013).
Stem cell transplantation
Owing to their multipotent capability, stem cells can differentiate into any cells to
replace the cell type that has been damaged. In addition, stem cells also secrete
neurotrophic factors to support the growth of the neurons. At present human embryonic
stem cells have been approved by U.S.FDA to apply in clinical trails for retinal pigment
epithelial (RPE) cell development. RPE subretinal transplant in RCS rats has been proved
to survive over 220 days (Lu et al., 2009). However, there is a potential risk that the stem
cell

proliferation

could

become

uncontrollable

and

a

tumor

could

develop.

Immunorejection of heterogenic stem cell transplant can also be a problem (Ong and da
Cruz, 2012). The biggest challenge in stem cell transplantation in vision restoration is the
synapse connectivity between the transplanted neurons and the local ones (Osakada and
Takahashi, 2015).
Optogenetic approach
The optogenetic approach is to genetically target light sensors to retinal cells and
make them responsive to light, thus replacing the function of the degenerated
photoreceptor cells (Bi et al., 2006). Our lab focuses on this approach for vision
restoration, and it is also the focus of my project.
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1.3 Optogenetic approaches
1.3.1 Optogenetic tools
One of the most promising optogenetic tools is channelrhodopsin-2 (ChR2), which
was found in green algae Chlamydomonas reinhardtii and is formed by channelopsin-2
(Chop2) and a retinal chromophore (Nagel et al., 2003). The ChR2 is a light activated
cation channel; upon light stimulation, the channel opens and leads to depolarization of
the cell membranes (Bi et al., 2006; Boyden et al., 2005). Another optogenetic tool is the
halorhodopsin from the archea Natronomonas pharaonis (NpHR) (Lanyi, 1986); it is a
light driven inward chloride pump that can lead to cell membrane hyperpolarization upon
light activation (Boyden et al., 2005; Zhang et al., 2009b). This means ChR2 expressing
cells can mimic ON cells whereas NpHR expressing cells can mimic OFF cells in the
retina. In order to understand the approaches used to implement the optogenetic strategy
to restoring vision, I will give a brief introduction on the vision signaling pathways.
1.3.2 Visual signaling pathways

Figure 1: The ON and OFF pathways of the mammalian retina (Wassle, 2004). OS/IS,
outer and inner segments of rods and cones; ONL, outer nuclear layer; OPL, outer
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plexiform layer; INL, inner nuclear layer; IPL, inner plexiform layer; GCL, ganglion cell
layer; RB, rod bipolar cells; AII, AII amacrine cells.
In the mammalian retina, there are three major layers of cells: photoreceptor cells in
the outer nuclear layer; bipolar cells, amacrine cells, and horizontal cells in the inner
nuclear layer; ganglion cells in the ganglion cell layer. Photoreceptor cells (first order
neuron) sense light and transduce the light signal into an electrical signal to depolarize or
hyperpolarize the bipolar cells (second order neuron); then the ganglion cells (third order
neuron) gather all the signals to send projections to the brain for integrated processing.
Both rod and cone photoreceptors depolarize in the dark and hyperpolarize in response
to light. Bipolar and ganglion cells are divided into ON and OFF cells that respond to light
with depolarization and hyperpolarization, respectively. Rod bipolar cells are ON bipolar
cells; signals of the rod pathway feed into the cone pathway through AII amacrine cells.
The AII amacrine cells transfer signals to the ON bipolar cells through gap junctions and
to the OFF pathway through inhibitory glycinergic synapses (Figure 1). What causes the
difference between ON and OFF cells is that ON bipolar cells express the metabotropic
glutamate receptors (mGluR6), while the OFF bipolar cells express ionotropic glutamate
receptors (Wassle, 2004).
1.3.3 Optogenetic approach by targeting retinal bipolar cells
The light sensors such as ChR2 can be targeted to each order of retinal neurons,
from photoreceptor cells to ganglion cells. Surviving cone photoreceptors as the targeting
sites have a special advantage because they are the only cell type existing in the fovea,
and the aggregation of cones endows this area the highest spatial acuity (Curcio and
Hendrickson, 1991). Targeting ChR2 to the rod bipolar cells and AII amacrine cells can
stimulate both ON and OFF responses in the downstream ganglion cells (Ivanova and
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Pan, 2009). In the condition that photoreceptor death has caused remodeling of the
remaining retina, targeting ChR2 to the ganglion cells will be the only option because
ganglion cells are the most resistant to remodeling (Jones and Marc, 2005; Kolomiets et
al., 2010). The proof-of-concept study for the latter has been demonstrated in animal
models (Bi et al., 2006).
My research focuses on the strategy of targeting ChR2 to ON bipolar cells (both rod
bipolar cells and ON cone bipolar cells) to restore vision instead of photoreceptors and
ganglion cells for the following reasons: 1) In patients who have retinal degenerative
diseases, their cone photoreceptors may already be severely damaged before application
of this optogenetic therapy; 2) targeting ON bipolar cells may preserve more of the visual
processing pathways compared to targeting ganglion cells, which would result in higher
vision acuity when applied in patients. However, a big challenge is to achieve AAVmediated high specificity and high efficiency of ChR2 expression in bipolar cells. Even
though our lab has developed an optimized bipolar cell specific promoter (Lu et al., 2016),
the AAV transduction efficiency to bipolar cells is still low. Our lab also reported recently
that the bipolar cell targeting is less efficient than ganglion cell targeting (Lu et al., 2018).
The low AAV transduction efficiency in retinal bipolar cells could be due to factors such
as physical barrier of the retina, AAV intracellular trafficking and capsid tropisms. My goal
is to address this problem and potentially make the vision restoration more efficient.
1.3.4 Adeno-associated virus as a vehicle
Adeno-associated virus (AAV) has been the most widely used and effective gene
delivery vehicle in retinal gene therapy (Buch et al., 2008; Dalkara and Sahel, 2014;
Vandenberghe and Auricchio, 2012); it is a nonpathogenic virus that contains a single
stranded DNA genome up to 4.7-kb and an outer capsid (composed of VP1, VP2, VP3
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structural protein). There are at least 12 serotypes of AAV that have been described, with
serotype 2 most widely used (Watanabe et al., 2013). The recombinant AAV2 was first
made by Hermonat and Muzyczka (1984), with a SV40 promoter driving the neo
resistance gene. This construct was successfully brought into cultured mammalian cells,
which proved the availability of foreign DNA sequence being introduced via AAV vectors
(Hermonat and Muzyczka, 1984). On December 19th, 2017, LUXTURNA (an AAV2based gene therapy for patients with RPE65 mutation-associated retinal disease) was
approved by FDA; it is the first AAV-based gene therapy approved in the US. Two
methods have been used for delivering AAV vectors to the retina in vivo; one is intravitreal
injection, and the other is subretinal injection. Subretinal injection has been widely used
given its advantage of avoiding the inner limiting membrane as well as its easier access
to photoreceptors (Surace and Auricchio, 2003). However, the fact that it can cause
retinal detachment and other damage cannot be ignored; besides, it only transduces AAV
vectors to a limited region of the retina (Dalkara et al., 2009a). In contrast, intravitreal
injection is less invasive and enables AAV transduction to any retinal cell type despite
differences in their efficiencies (Dalkara, 2013).
1.3.5 Adeno-associated virus-mediated targeting to retinal bipolar cells
Promoters are critical for cell-targeted specificity and efficiency because they initiate
particular gene transcription. CMV and CAG are ubiquitous promoters; Bi et al. (2006)
delivered AAV2 vectors in mouse retinas with a CMV enhancer/chicken β-actin (CAG)
promoter, leading to transgene expression in various cell types: mostly ganglion cells,
some amacrine/horizontal cells, and few bipolar cells. My project focuses on targeting
ChR2 to ON bipolar cells; therefore, a selective promoter for ON bipolar cells is required.
Since metabotropic glutamate receptors (mGluR6) are specifically expressed in ON
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bipolar cells (Brandstatter et al., 1998) and the Grm6 gene encodes the mGluR6,
delivering the gene under the control of regulatory elements intraocularly should target
ON bipolar cells in particular. It was reported that targeted expression of transgene in ON
bipolar cells can be achieved by using the SV40 eukaryotic promoter fused with the 200base pair enhancer sequence of the Grm6 gene (Grm6En) (Cronin et al., 2014; Doroudchi
et al., 2011; Lagali et al., 2008; Mace et al., 2015). However, AAV vectors containing this
200bp enhancer and SV40 promoter have relatively low expression efficiency in bipolar
cells (Lu et al., 2016). In addition, the light intensity required for activating ChR2 (1014
photons cm-2 s-1) is much higher than that of the opsins from rod (106 photons cm-2 s-1)
and cone (1010 photons cm-2 s-1) photoreceptors (Mace et al., 2015). In order to enhance
the light responsiveness of the bipolar cells, the expression level of ChR2 must be
increased. Our lab has developed an optimized mGluR6 promoter construct (In4s+In3Grm6En-mGluR500P) which replaces the mSV40 promoter (mSV40P) by the 500 bp
mGluR6 promoter and adds a shortened intron 4 and an intron 3 (In4s-In3) enhancer
sequence (Lu et al., 2016). This leads to a marked enhancement in AAV transduction
efficiency in retinal bipolar cells as well as a reduction in off targeting (Figure 2). Moreover,
the optimized mGluR6 promoter construct was found to mainly target rod bipolar cells
(Figure 3).
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Figure 2: Comparison of AAV-mediated mCherry expression with different mGluR6
promoter constructs in the mouse retinas (Lu et al., 2016). (a-f) Left/middle panels: wholemount fluorescence images acquired at the inner nuclear layer (left panels) and ganglion
cell layer (middle panels). Right panels: fluorescence images of retinal vertical sections
after immunolabeling with anti-mCherry antibody. (g) Comparison of mCherry
fluorescence intensities with different mGluR6 promoter constructs. (h) Comparison of
cell densities of the mCherry-expressing bipolar cells with different mGluR6 promoter
constructs. The data are shown as mean ± SD. The asterisk indicates statistically
significant differences at p<0.05 (one-way analysis of variance).
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Figure 3: Immunostaining of mCherry-expressing bipolar cells transduced by the virus
vectors containing modified mGluR6 promoter constructs. The mCherry expression was
driven by the promoter construct of 200E-mGluR500P (a-b) and In4s-In3-200EnmGluR500P (c-d). Retinal whole-mount (a,c) and vertical section (b,d) were colabeled for
mCherry and PKC (rod bipolar cell marker) (Lu et al., 2016).
1.3.6 Factors that affect the AAV transduction in the retina
Physical barriers and inner limiting membrane
First of all, the bipolar cell layer is located in the middle of the retina, which means
that it is difficult for viruses to access bipolar cells with either intravitreal or subretinal
delivery. For our purpose, we prefer to inject virus through the vitreous space; hence the
second barrier shows up: the inner limiting membrane. The inner limiting membrane (ILM)
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is a basement membrane that resides between the vitreous body and the retina as a
boundary. Functionally, it is a layer that facilitates the attachment between the neuroretina
and the vitreous body. Under a high resolution electron microscope, the ILM consists of
two thin layers of lamina lucidas with a layer of lamina densa in between (Halfter et al.,
2008). Under a conventional light microscope, like a surgical microscope, the ILM
appears to be a transparent layer covering the neuroretina. Nowadays, peeling off the
ILM layer has been an option for many retinal surgical conditions, like macular hole. It is
believed that by peeling off the ILM, traction from the vitreous body against the macula is
released and since the ILM is more or less functionally dispensable, getting rid of the ILM
for better medical outcome appears to be extremely appealing (Mester and Kuhn, 2000).
The composition of the inner limiting membrane contains 10 types of high-molecular
weight extracellular matrix proteins, including nidogen1 and 2 (laminin), collagen II, and
heparin sulfate proteoglycans (HSPG), agrin, perlecan and collagen IV (Halfter et al.,
2008). This is of importance because it explains how the ILM affects the diffusion of
different serotypes of AAV. For example, AAV2 binds to the HSPG and laminin, which
facilitates its accumulation at the ILM and further access to the ganglion cell layer, while
AAV5 doesn’t have a binding site at the vitreoretinal junction. Interestingly, a robust
expression of AAV5 in various retinal cell types can be achieved following intravitreal coinjection with a proteolytic enzyme Pronase E, suggesting the ILM may constitute a barrier
for AAV penetration into the retina (Dalkara et al., 2009a).
Although the ILM is relatively thin in rodents, larger mammals possess a much thicker
ILM that differs in thicknesses from region to region of the retina. In primates and human,
the ILM is thinnest in the fovea and thickest around the fovea; the ILM above the retinal
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vessels is thinner than in the surroundings (Matsumoto et al., 1984). Accordingly, AAV2
transduction in marmoset retinas is best in the fovea and above retinal vessels, almost
absent near the fovea, and modest in peripheral areas (Ivanova et al., 2010). Therefore,
enzymatic treatment of the ILM is necessary for the future application of the optogenetic
approach clinically. Microplasmin has been demonstrated to disrupt the border between
the ILM and vitreous body in macaque, resulting in an increased transduction similar to
the effect of pronase E on rodents (Yin et al., 2011). Plasmin is a trypsin-like serine
protease; it can dissolve laminin and fibronectin in ILM, as well as facilitate extracellular
matrix degradation (Liotta et al., 1981). In this study, I examined the effect of plasmin in
improving AAV-mediated transgene expression in the retinal bipolar cells. The results are
presented in Chapter 4.
AAV serotypes
Hybrid AAV serotypes
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Figure 4: Schematic representation of hybrid AAV production and targeting (Auricchio,
2003).
AAV has tropisms towards various tissue types, and tissue specificity is due to
different AAV capsid serotypes. Numerous serotypes of AAV have been described, with
serotype 2 most extensively studied. The recombinant AAV2 (rAAV2) genome contains a
therapeutic gene sequence with one ITR (inverted terminal repeat) sequence on each
end, followed by two opening reading frames: rep and cap. The rep2 gene codes for
proteins that are necessary to maintain the AAV2 life cycle (replication); the cap2 gene
codes for the AAV2 capsid protein that determines the AAV2 tropism. By packaging AAV2
genome with capsids of other serotypes, hybrid AAV vectors are produced (Figure 4).
These pseudotyped AAVs possess advantages over the original ones in their ability to
avoid the pre-existing immunity, as well as gaining a variety of tissue tropisms according
to the different outer capsids (Auricchio, 2003). Intravitreal application of rAAV2/2 and
rAAV2/8 particularly transduced to retinal ganglion cells (RGCs), while subretinal injection
of rAAV2/5, rAAV2/8 and rAAV2/9 resulted in transduction of cone photoreceptors
(McClements and MacLaren, 2013). In addition, AAV2/8 vectors driven by the mGluR6
promoter can get a strong and stable transgene expression in the mouse retinal ON
bipolar cells by subretinal injection (Doroudchi et al., 2011). However, no one has tested
the AAV2/8 vector with mGluR6 promoter through intravitreal injection. In my preliminary
work, I did intravitreal injection of the virus construct, but the result showed barely any
transgene expression on bipolar cells (data not shown).
Single capsid mutation
Since the phosphorylation of surface-exposed tyrosine residues on AAV capsids acts
as a signal for ubiquitination, mutations on tyrosine can help the AAV vectors escape the

14
proteasome degradation process (Zhong et al., 2008a; Zhong et al., 2008b). There are
all together seven surface-exposed tyrosine residues in the VP3 common region of the
capsid, Y252, Y272, Y444, Y500, Y700, Y704, and Y730 (Zhong et al., 2008b). AAV2 with
an original capsid has been proved to target mainly ganglion cells, frequently horizontal
cells and amacrine cells, and occasionally bipolar cells following intravitreal injection in
mouse eyes (Bi et al., 2006). Petrs-Silva et al. (2009) made tyrosine to phenylalanine
single point mutations (Y444F and Y730F) on the AAV2 capsid and reported that both of
them showed enhanced RGC transduction after intravitreal injection. Moreover, Y444F
mutation made on rAAV2/2 vectors showed photoreceptor transduction after intravitreal
injection and RGC transduction following subretinal injection, indicating an improved
ability to penetrate throughout the retinal layers (McClements and MacLaren, 2013). In
our lab, we have demonstrated that AAV2 vectors with the Y444F mutation could
significantly increase the transduction efficiency in both ganglion cells and bipolar cells
(under ubiquitous CMV promoter) via intravitreal injection; while without this mutation, the
AAV2 vectors could only reach the ganglion cell layer (Lu et al., 2013). Therefore, our
current AAV2 vectors with the mGluR6 promoter are all made with the Y444F mutation,
resulting in good expression restricted to bipolar cells.
Multiple capsid mutations
Multiple combinations of Y-F mutations (from double to septuple) on AAV2 vectors
have been tried on the mouse retinas through vitreous delivery (Petrs-Silva et al., 2011).
All mutants showed similar reporter gene expression pattern from ganglion cell layer
through the photoreceptor layer, with the quadruple (Y272,444,500,730F) and pentuple
(Y272,444,500,704,730F) mutant even extending to the RPE layer. In addition to tyrosine
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to phenylalanine mutations, threonine (T) to valine (V) mutations (T-V mutations) have
also been tested. Both the Y-F and T-V/A mutations enhance AAV transduction by
blocking the capsid residue phosphorylation; therefore, the capsids can avoid
ubiquitination and subsequent proteasome degradation (Aslanidi et al., 2013; Petrs-Silva
et al., 2009). Among 17 surface-exposed threonine residues on the AAV capsid, four of
them were shown to increase AAV transduction efficiencies in human HEK293 cells after
T-V mutation (T455V,T491V,T550V,T659V), with the T491V the best-performing one.
The T491V mutation was then combined with the triple mutant Y444,500,730F to form
the quadruple mutant Y444,500,730F+T491V, which was demonstrated to transduce
mouse hepatocytes efficiently both in vivo and in vitro (Aslanidi et al., 2013). Shannon
Boye’s group gained robust photoreceptor expression in mouse retinas by using a
quintuple AAV2 mutant (Y272,444,500,730F+T491V) driven by the human rhodopsin
kinase promoter (hGRK1) via intraviteal delivery (Kay et al., 2013).
In vivo-directed evolution approach

Figure 5: Molecular model of AAV2 with the insertion LALGETTRP (shown in orange).
The interactions between the inserted loop and the other surface loops of the capsid
likely play a role in the novel properties of the virus (Dalkara, 2013).
Another method to increase the AAV diffusion capability by altering their capsid
protein is the in vivo-directed evolution approach (Figure 5). In 2013, Dalkara et al.
modified the AAV2 capsid by making a 588LALGETTRP insertion (7mer insertion), leading
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to a lower binding ability to its primary receptor, thus a higher possibility of penetration
through the retinal layers as well as the inner limiting membrane. The 7mer insertion
works by impacting arginine residues in loop 4 within the HSPG binding domain of the
AAV2 capsid, therefore the affinity between AAV2 and its primary receptor is lowered.
This AAV2 variant with 7mer insertion is called 7m8, which has shown higher infection
rates than AAV2 in cultured cells. They further applied 7m8 carrying GFP sequence
driven by a ubiquitous CAG promoter to the mouse retinas by intravitreal injection, getting
a result of a pan-retinal gene expression. More excitingly, they also targeted
photoreceptor cells specifically by replacing the CAG promoter with a rhodopsin promoter
(Dalkara, 2013). The transduction ability of 7m8 will make it a potent tool for targeting any
retinal cell types of interest, including bipolar cells, after intravitreal administration.
Therefore, I hypothesize that, together with our optimized mGluR6 promoter, the 7m8
vector will dramatically increase the ChR2 expression in RBCs. In my preliminary data,
one month after intravitreal injection, ChR2-GFP expression in bipolar cells driven by 7m8
vector with In4s+In3-Grm6En-mGluR500P promoter construct can be clearly seen (data
not shown), while that by original AAV2 is very weak without staining. This suggests the
7m8 works better than AAV2 in targeting RBCs.
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Figure 6: AAV-mediated expression patterns in the marmoset retina. The mCherry
expression was driven by In4s-In3-200En-mGluR500P promoter construct with AAV2/2Y444F mutation (a) and AAV2.7m8-Y444F mutation (b). The three panels on the right are
the magnified images: 1, the fovea; 2, the representative peripheral regions of the retina;
3, the representative regions containing blood vessels. (c) The higher magnification
image of the fovea in a. (d) The higher magnification image of the fovea in b. (Lu et al.,
2016).
A recently published paper in our lab demonstrated that 7m8 vectors with a Y444F
capsid mutation had a more robust transgene (mCherry) expression in the marmoset
retina than AAV2 vectors with a Y444F capsid mutation (Figure 6). However, no one has
tested the effect of multiple mutations on 7m8. In order to produce the most efficient virus
vectors for improving transgene expression in RBCs, I planned to make the quadruple
mutations (Y444,500,730F+T491V) on the 7m8 vectors with mGluR6 promoter, and
examine the effect after one month of intravitreal injection. However, our virus vectors
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could not be packaged by the Virovek company. The quadruple mutations made on the
7m8 capsid likely caused instability in capsid formation. Therefore, the experiments were
discontinued.
AAV trafficking
Intracellular trafficking

Figure 7: Schematic diagram of AAV intracellular trafficking process (Schultz and
Chamberlain, 2008).
The AAV intracellular trafficking process is displayed in Figure 7. To enter a cell, AAV2
must first attach to the target cell membrane by binding to attachment receptors. Cell
infection requires both primary receptors and coreceptors. Different transduction
susceptibilities of various cells rely on different combinations of their receptors (Douar et
al., 2001). The primary attachment receptor for AAV2 is heparan sulfate proteoglycans
(HSPG), which is proved to affect AAV2 transduction efficiency directly (Summerford and
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Samulski, 1998a). Human fibroblast growth factor receptor 1 (FGFR1) can work as a
coreceptor for HSPG to enhance the overall efficiency of AAV2 adherence (Qing et al.,
1999). There are also some other coreceptors for AAV2 such as integrin αVβ5, integrin
α5β1, and hepatocyte growth factor receptor (Asokan et al., 2006; Kashiwakura et al.,
2005; Summerford et al., 1999). Following attachment to the target cell, AAV2 then
undergoes endocytosis through clathrin-coated vesicles (Bartlett et al., 2000). After
entering the cell, the internalized vesicles become early endosomes, and then late
endosomes. The mammalian cells use two sets of systems to degrade the proteins. The
lysosome, which contains acid proteases and hydrolases, has long been studied for its
function in breaking down endocytosed extracellular proteins. Another important system
includes proteasomes, which are protein complexes that mainly function in digesting
unneeded or damaged proteins. To transport the aimed protein to the proteasome, the
substrate needs to be marked by ubiquitin (Lee and Goldberg, 1998). The substrate
ubiquitination requires three functional proteins: activating enzyme (E1), conjugating
enzyme (E2), and ubiquitin ligase (E3). Duan et al. (2000) applied E3 inhibitor dipeptides
H-Leu-Ala-OH and H-His-Ala-OH with AAV vectors to the polarized human airway
epithelia and showed an enhanced AAV transduction. Direct inhibition of proteasome
activity shows even better effect in strengthening AAV expression; Doxorubicin and MG132 are proteasome inhibitors that have been proved to have a dramatic AAV
enhancement effect (Douar et al., 2001; Zhang et al., 2009a).
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Proteasome inhibitors

Figure 8: Schematic diagram of the 26S proteasome structure (Ventii and Wilkinson,
2008).
The classical proteasome protein degradation pathway is the ubiquitin-conjugated
26S proteasome pathway (Goldberg, 2003). The 26S proteasome is composed of a 20S
core particle that catalyzes the proteolytic activity, and a 19S particle that regulates the
degradation process (Figure 8). The 19S particle can recognize the ubiquitin-marked
substrates, unfold them, and deliver them to the 20S core to be degraded. The 20S core
is a barrel-shaped complex, with two rings of 7β subunits in the center, and two rings of
7α subunits on the outside. The two outer rings surround an opening, through which the
substrate enters for degradation. Some of the β subunits inside are active proteolytic sites,
taking responsibility for the chymotrypsin-like, trypsin-like, and caspase-like proteasome
activities (Kish-Trier and Hill, 2013). Although most of the proteasome substrates go
through this traditional pathway, some proteins are digested by the proteasome in an
ubiquitin-independent manner (Erales and Coffino, 2014). In other words, these proteins
are broken down by the 20S proteasome itself without the coordination of the 19S particle.
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In fact, 50% of proteasomes in mammalian cells exist as the free 20S form, while only
30% of those exist as the 26S combination. Instead of dealing with the ubiquitinated
polypeptides, the substrates for the 20S proteasome are damaged proteins; only the
unstructured proteins can enter the narrow opening of the 20S proteasome without being
unfolded by the 19S particle (Ben-Nissan and Sharon, 2014).

Figure 9. Schematic diagram of the effect of proteasome inhibitors on AAV2 transduction
in a cell.
Proteasome inhibitors have been reported to increase transduction of various types
of AAVs (AAV serotype 1-8) to different tissues (Chaanine et al., 2014), as well as to
alleviate the immune responses against AAV capsids (Karman et al., 2012). The working
mechanism of proteasome inhibitors on improving AAV transduction is displayed in Figure
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9. Normally after AAV2 virus vectors enter a cell, they are processed by the early
endosome and late endosome and are then transported to the proteasome for
degradation. With the application of proteasome inhibitors, the digestive function of
proteasome is blocked, which allows the AAV vectors to enter the cell nucleus and
express the transgene they carried. MG132 is the first synthesized proteasome inhibitor;
it is a tripeptidyl aldehyde derived from the substrates of the chymotrypsin-like active site
(most important site for protein degradation). Further, bortezomib was produced by
replacing the aldehyde with a boronate head in addition to some modifications in the
peptide backbones (Goldberg, 2012). Bortezomib is the first U.S.FDA approved
proteasome inhibitor to be tested in clinics (Chen et al., 2011). Both the MG132 and
bortezomib bind with the 20S core β-subunit, inhibiting primarily the chymotrypsin-like
proteasome activity, but also the caspase-like activity when the concentrations are high
(Goldberg, 2012; Yan et al., 2004). Doxorubicin and aclarubicin are nonpeptide
proteasome inhibitors that are also used clinically as anthracycline anticancer drugs;
similar to the bortezomib, they block the chymotrypsin-like proteolytic activity of the
proteasome (Yan et al., 2004). MG132, bortezomib, doxorubicin and aclarubicin have all
been proven to have a dramatic effect in enhancing AAV transduction in either cultured
cell lines or small animal models (Douar et al., 2001; Mitchell and Samulski, 2013;
Monahan et al., 2010; Yan et al., 2004; Zhang et al., 2009a). However, no one has
evaluated these drugs in the retina for improvement of AAV-mediated transgene
expression. I hypothesize that with the help of these proteasome inhibitors, less AAV2
vectors will be degraded by proteasomes in the RBCs and the AAV-mediated transgene
expression level will be remarkably increased. I examined the effects of MG132,
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doxorubicin, and aclarubicin by co-injecting them with rAAV2 virus in the vitreous space
of C57BL/6J mouse eyes.
Pharmacokinetics of doxorubicin
Hu et al., 2006 examined the pharmacokinetics of doxorubicin in the rabbit eye
following intravitreal injection. They did dissection of the rabbit eyes at 0.167, 0.5, 1.0,
1.5, 2.0, 3.0, 4.0, 5.0, 6.0, 8.0, and 12.0 hours after intravitreal injection of 5 μg
doxorubicin. They reported that doxorubicin could not be detected in all ocular tissues
(including vitreous body, iris, retina/choroids, and sclera) 12 hours after injection.
Moreover, doxorubicin was not detectable in the retina 8 hours after injection (Hu et al.,
2007). In order to determine an optimal delivery protocol for doxorubicin in the mouse eye,
I tested the efficacy of doxorubicin on AAV-mediated mCherry expression in the retinal
bipolar cells by administrating doxorubicin twice with an 8-hour interval. The results are
presented in Chapter 2 Figure 13.
Cytotoxicity of doxorubicin
Doxorubicin as an anthracycline chemotherapy regimen was well known to cause
cardiotoxicity in cancer patients (Chatterjee et al., 2010; Kumar et al., 2012). Doxorubicin
also works as a nonpeptide proteasome inhibitor, and was previously reported to induce
neurotoxicity to rat cortical neurons (Lopes et al., 2008). The mechanisms of
anthracycline-induced

cytotoxicity

involve

iron-dependent

and

iron-independent

mechanisms (Menna et al., 2007). The intracellular iron levels are physiologically
regulated by ferritin and transferrin receptor; the transcription of the genes coding for
ferritin and transferrin receptor levels are regulated by iron regulatory proteins—IRP-1
and IRP-2. IRPs regulate the levels of ferritin and transferrin receptor by binding to the
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conserved iron regulatory elements (IRE) in the ferritin and transferrin mRNAs (Cairo and
Pietrangelo, 2000). Doxorubicin is able to switch the cytoplasmic aconitase enzyme into
IRP-1, which facilitates iron uptake to the cell and increases the intracellular free iron
levels. This process is highly toxic to the cells (Minotti et al., 2001). Another mechanism
of doxorubicin-induced cell damage is the formation of the drug-iron complex which
catalyzes the formation of hydroxyl radical and causes DNA damage (Muindi et al., 1984).
Dexrazoxane (Zinecard) is a FDA-approved drug that is used to reduce the anthracyclineinduced cytotoxicity. The active form of dexrazoxane is similar to EDTA, which chelates
iron and limits the formation of anthracycline-iron complexes, and therefore reduces the
generation of free radicals and the subsequent oxidative damage to cells (Ichikawa et al.,
2014; Langer, 2014). Previous studies on the antidote effect of dexrazoxane are mainly
limited to the anthracycline-induced cardiotoxicity (Ichikawa et al., 2014; Langer, 2014;
Swain et al., 1997b). However, the effect of dexrazoxane has not been tested on retinal
neurons treated with doxorubicin.
Arsenic trioxide

Figure 10: Role of arsenic trioxide on AAV transduction (Mitchell et al., 2013).
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Before trafficking to the nucleus, AAV particles first move to the perinuclear region
and accumulate there. This region is the microtubule-organizing center (MTOC); the AAV
virions are enclosed in late endosomal or lysosomal compartments. They arrive at the
MTOC by travelling along the microtubules (Nicolson and Samulski, 2014; Xiao and
Samulski, 2012). If the viruses cannot enter the nucleus, they will eventually be degraded
by the proteasomes. Arsenic trioxide (As2O3) is a FDA-approved chemotherapeutic agent
that was shown to enhance AAV transduction by stabilizing the virus accumulation at the
perinuclear region. More viruses were preserved to escape from the MTOC and continued
a productive nuclear trafficking with the treatment of As2O3 both in vitro and in vivo
(Mitchell et al., 2013). Mitchell et al. claimed the drug effect of As2O3 was dependent on
formation of reactive oxygen species (ROS) (Figure 10). They also reported the
transduction efficiency could be increased by As2O3 in multiple AAV serotypes, including
rAAV2, rAAV6, rAAV8, rAAV9, and self-complementary rAAV2. However, the effect of
arsenic trioxide on AAV-mediated transgene expression has never been tested in neural
cells. Therefore, I co-injected arsenic trioxide and AAV2 virus (with a bipolar cell-specific
promoter carrying mCherry transgene) to examine the efficacy of arsenic trioxide on AAV
transduction in the mouse retinal bipolar cells. My result showed that the mCherry
expression level had no difference among retinas treated with 500 μM As2O3, 1mM As2O3,
and control (data not shown). Therefore, the virus accumulation effect of arsenic trioxide
at the perinuclear region couldn’t be proven to increase AAV2 transduction efficiency in
RBCs, at least at concentrations up to 1mM.
Nuclear trafficking
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The nucleus entry process is slow and inefficient, leaving most of the AAV
accumulating in the perinuclear area, while only a small fraction of virus particles passes
the nuclear membrane in cultured cells (Bartlett et al., 2000). The viral particles that are
not entering the nucleus will be finally degraded by the proteasomes. Although there is
lack of a well-defined mechanism, it was suggested the rAAV2 utilizes parts of the
canonical nuclear import pathway to enter the nucleus. After entering the nucleus, the
AAV particles need to remove their outer capsids. Then the single strand AAV DNA must
synthesize a second strand for subsequent transcription, which constitutes an important
rate-limiting step. Zhong et al. (2007) presented that the cellular chaperone protein
FK506-binding protein 52 (FKBP52) plays an inhibiting role on AAV2 second strand DNA
synthesis, whose tyrosine residues are phosphorylated by the epidermal growth factor
receptor protein tyrosine kinase (EGFR-PTK). Srivastava’s lab reported that
dephosphorylation of FKBP52 protein at tyrosine residues by heat-shock protein 90
(HSP90) and T-cell protein tyrosine phosphatase (TC-PTP), as well as dephosphorylation
at serine/threonine residues by protein phosphatase 5 (PP5) were able to augment AAV
second strand synthesis and in consequence enhance AAV transduction in HeLa cells
(Jayandharan et al., 2008; Qing et al., 2003; Zhong et al., 2004). Perturbing EGFR-PTK
signaling by using a specific inhibitor-tyrphostin-23 can also increase AAV transduction
efficiency (Zhong et al., 2007). Hydroxyurea was also reported to increase AAV
transduction; it mobilizes virus vectors into the nucleoplasm, which likely facilitates
uncoating and subsequent gene expression (Johnson and Samulski, 2009). In my
preliminary study, I tested the effects of tyrphostin 23 and hydroxyurea on rAAV2-
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mediated transgene expression in RBCs, but the results suggested no difference between
treated retinas and control (data not shown).
Self-complementary AAV
As I mentioned before, one of the AAV transduction rate-limiting steps is the
conversion of the single-stranded DNA (ssDNA) to double-stranded DNA (dsDNA) after
translocation of AAV to the nucleus. There are two mechanisms for AAV to generate a
complementary double strand DNA structure. The conventional one requires a secondary
strand synthesis: the ITR sequences at each end of the genome form hairpin structures,
which act as replication primers to extend a new complementary strand with the
assistance of host cell DNA polymerases (McCarty, 2008). Another alternative
mechanism is the strand annealing (SA), or interstrand base pairing of two matched
strands from different viruses (Nakai et al., 2000). Despite the coexistence of two
mechanisms, conventional DNA second strand synthesis makes the most contribution to
AAV transduction (McCarty, 2008; Zhong et al., 2008c). No matter which mechanism is
preferable, the need for dsDNA transformation becomes an obstacle for AAV transduction
efficiency. Utilizing self-complementary AAV (scAAV) may avoid the limiting factors
associated with second strand synthesis. In the scAAV vector, both of the two base-paired
DNA strands are packaged as a whole and stabilized by deleting the resolution site
sequence from one terminal repeat (McCarty et al., 2003; Wang et al., 2003). This design
can substantially enhance the transgene expression regardless of the DNA synthesis and
vector doses (McCarty, 2008; McCarty et al., 2001). Furthermore, the single stranded
virus genome is stable only within the protection of the capsid shell; while the built-in
double stranded genome in scAAV makes it more stable (Thomas et al., 2004). However,
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the base-paired DNA construct also limits the gene carrying capability because the length
of dsDNA has to be reduced by half for packaging (McCarty, 2008). Even with this
limitation, injection of scAAV serotype 2 to mouse eyes has shown rapid expression in
RPE cells and photoreceptor cells via subretinal delivery, and widespread RGC
expression via intravitreal delivery (Yokoi et al., 2007). scAAV2/2, scAAV2/5, and
scAAV2/8 also yielded higher and faster transgene expression, with different transduction
selectivity and efficiency accordingly (Natkunarajah et al., 2008). In addition, scAAV
vectors can be modified with Tyr-Phe mutations; scAAV2 Y444F and scAAV8 Y733F are
two potent mutants that have revealed high efficiency for cell targeting (Petrs-Silva et al.,
2009). Given the information on how scAAV may help to increase AAV expression, in my
preliminary study, I tested scAAV vectors with mGluR500P promoter carrying mCherry
transgene to target RBCs. My results showed that the mCherry expression was minimally
enhanced with the application of self-complementary AAV (data not shown). Since the
small increase of the transduction efficiency of the sc-construct is at the cost of a shorter
virus construct, which will limit the length of the gene it carries, I did not further develop
newer scAAV vectors.
1.4 Hypotheses
Targeting ChR2 in bipolar cells is one of the promising approaches for restoring vision.
AAV-mediated targeting of ChR2 to RBCs has been achieved using mGluR6 promoter
constructs. However, the AAV transduction efficiency in bipolar cells is low. The goal of
my project is to improve AAV trafficking efficiency in bipolar cells. I tested my hypotheses
that poor virus accessibility to bipolar cells and virus degradation during intracellular
trafficking are two main barriers for the efficient AAV transduction to bipolar cells. I used
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mCherry as the transgene instead of ChR2 to examine the AAV transduction efficiency.
Hypothesis 1: Proteasome inhibitors would improve AAV transduction efficiency
in retinal neurons.
Hypothesis 2: Enzymatic digestion of inner limiting membrane would increase the
number of AAV-transduced retinal neurons.
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CHAPTER 2: EVALUATION OF THE EFFECT OF PROTEASOME INHIBITORS ON
AAV-MEDIATED TRANSDUCTION EFFICIENCY IN RETINAL BIPOLAR CELLS
2.1 Hypothesis
Proteasome inhibitors would improve AAV transduction efficiency in retinal neurons.
2.2 Rationale
Adeno-associated virus (AAV) has been the most widely used and effective gene
delivery vehicle in retinal gene therapy (Buch et al., 2008; Dalkara and Sahel, 2014;
Vandenberghe and Auricchio, 2012). However, the AAV-mediated transduction efficiency
in retinal bipolar cells is generally low (Lu et al., 2016). One of the limiting factors is the
virus degradation by proteasomes during AAV intracellular trafficking (Nonnenmacher
and Weber, 2012). Therefore, I hypothesized that application of proteasome inhibitors
would assist the AAV virus to escape the capsid protein degradation activity of the
proteasome. In this way, more AAV viruses can be available for nuclear entry, thus
improving gene expression. In this study, I tested the effect of three proteasome inhibitors,
doxorubicin, aclarubicin, and MG132, on AAV-mediated transduction efficiency in retinal
bipolar cells. In order to compare the AAV-mediated transgene expression in the retinal
bipolar cells, AAV virus vectors with a bipolar cell-specific promoter carrying an mCherry
sequence were used via intravitreal injection.
2.3 Experimental design and method
Animals and materials
C57BL/6J mice were purchased from Jackson Laboratory (Bar Harbor, ME, USA).
Experiments and procedures were approved by the Institutional Animal Care and Use
Committee (IACUC) at Wayne State University and were in accordance with the NIH
Guide for the Care and Use of Laboratory Animals.
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Viral vectors were packaged at Virovek (Hayward, CA, USA), with the construct
AAV2 (Y444F)-intro4&3-Grm6En-mGluR500P-mCherry-hGHpA. Proteasome inhibitors
were purchased from commercially available sources: doxorubicin (Thermo Fisher
Scientific, Waltham, MA), aclarubicin (Santa Cruz Biotech, Dallas, TX), and MG132
(Cayman Chemical, Ann Arbor, MI).
Virus injection
Virus injections were performed in C57BL/6J mice at the age of about one month.
Briefly, mice were anesthetized by intraperitoneal injection of a mixture of 120 mg/kg
ketamine and 15 mg/kg xylazine. Under a dissecting microscope, a small perforation was
made in the temporal sclera region with a sharp needle. Viral vectors at a concentration
of ~5 x 1012 vg/mL were co-injected with saline or proteasome inhibitor solutions into the
intravitreal space through the perforation with a 10 μl Hamilton syringe with a 32-gauge
blunt-point needle. Each eye was injected bout 1.5 μl injection solution. In the control
group, AAV virus was co-injected with saline only. The injection solution preparation
containing AAV virus and different proteasome inhibitors is listed in Table 1. To eliminate
the selection bias, each mouse was given 2 different treatments at the same time--virus
with one dose of the drug was injected in the left eye, and another dose was injected in
the right eye. The dose ranges of the drugs were chosen based on previous research
(Yan et al., 2002; Yan et al., 2004; Zhang et al., 2009a).The expression was examined
about 1 month and 3 months after the viral injection.
Quantitative fluorescence and cell density measurements
Mice were deeply anesthetized with CO2 asphyxiation followed by decapitation.
Eyecups were fixed in 4% paraformaldehyde in 0.1 M phosphate buffer (PB) for 20
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minutes. Retinas were dissected in PB solution, flat mounted on slides, and coverslipped.
Images were acquired using a Zeiss Axio Imager 2 microscope with an Apotome 2
oscillating grating to reduce out-of-focus stray light (Apotome; Carl Zeiss Microscopy
GmbH, Jena, Germany). Image projections were constructed by collapsing individual zstacks of optical sections onto a single plane in ZEN software (Carl Zeiss). Since
transgene expression was not always evenly distributed throughout the retina (peripheral
area better than center area), images taken from the peripheral area (~2 mm from the
optic disc) were used for comparison. In each retina, 8-10 images (at 40X magnification)
were taken under the Zeiss Axio Imager 2 microscope. For the purpose of comparing the
mCherry transgene expression in the retinal bipolar cells, images were taken from wholemount retina at the inner nuclear layer without mCherry antibody enhancement under the
same fixed exposure time.
Quantifications for fluorescent intensity and cell density were performed using
ImageJ software (NIH). The fluorescent intensity was measured as optical density. The
‘Image – Adjust – Auto Threshold’ function of the software was used to select the cells
(the method “mean” was used to set the auto threshold). The ‘Analyze – Measure’ function
was used to obtain the Area of the cells (total area of the cells in each image, measured
in square pixels) and the Integrated Density (IntDen). The average fluorescence intensity
was calculated as IntDen/Area (Zhao et al., 2014). The fluorescence intensity was
displayed as the mean ± SD of the average fluorescence intensity of all measured cells.
The number of retinas examined was displayed as “n” on each column in the histogram.
The plot profile figures were generated from ImageJ software. The bipolar cell density
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was compared as the mean ± SD of the cell number within an image region of 0.0369
mm2 (at inner nuclear layer, 40X magnification).
Immunohistochemistry
For immunostaining of whole-mount retinas, the retinas were incubated for 2 hrs in
a block solution containing 5% ChemiBLOCK (Millipore Corp., Bedford, MA, USA), 0.5%
Triton X-100 and 0.05% sodium azide (Sigma-Aldrich, St. Louis, MO, USA). The primary
antibody used in this study was goat anti-mCherry (1:2000; Biorbyt, Cambridge, UK). The
secondary antibody was conjugated to Alexa 555 (1:1000). The primary antibody was
diluted in the same solution and applied for two days at room temperature (RT). The
retinas were then washed several times, followed by incubation in the secondary antibody
for one day at RT.

Table 1: Preparation of the injection solutions containing AAV virus and proteasome
inhibitors
2.4 Results
I examined three proteasome inhibitors, doxorubicin, aclarubicin, and MG132, on
AAV-mediated transduction efficiency in retinal bipolar cells in C57BL/6J mice. I first
examined the effect of the proteasome inhibitors on the expression level of mCherry in
bipolar cells one month after virus injection. My results show that doxorubicin at the
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concentration of 300-800 μM improved the expression of mCherry with the most effective
concentration at 300 μM (Figure 11a-e). At the concentration of 300 μM, 500 μM, and 800
μM, doxorubicin increased the intensity of mCherry by 68.2%, 32.4%, and 31.7%,
respectively (Figure 11u). On the other hand, no significant effect was observed for
aclarubicin (50 μM, 100 μM) and MG132 (100 μM, 200 μM, 500 μM) (Figure 11f-j, u).
Figure 11k-t are the plot profiles of Figure11a-j. Interestingly, the single cells that
represent the maximum mCherry expression level in each group treated with doxorubicin
200-800 μM actually displayed similar pixel intensities (Figure 11l-o). The differences of
the mean fluorescence intensities in these groups (Figure 11b-e, u) seemingly correlate
with the number of bipolar cells that have high mCherry expression levels (Figure 11l-o).
Therefore, I counted the number of bipolar cells that have a mCherry expression level
above 0.05 RFU/pixel2 within an image region of 0.0369 mm2 in retinas 1 month after
being treated with AAV virus with or without different proteasome inhibitors. I set 0.05
RFU/pixel2 as the threshold according to the maximum single cell fluorescence intensity
in the control. For example, in Figure 11k, the fluorescence intensity of the bestexpressing cell is between 0.05-0.10 RFU/pixel2; therefore, a threshold of 0.05 can just
include the cells that have high expression. My results show that the density of bipolar
cells with a mCherry expression above 0.05 RFU/pixel2 in retinas treated with AAV and
300, 500, or 800 μM doxorubicin was 24.3, 15.8, or 10.4 times higher compared with that
in retinas treated with AAV alone; while retinas treated with AAV and 200 μM doxorubicin
did not show a statistical difference (Figure 11v). Since doxorubicin is a fluorescent
molecule (Motlagh et al., 2016), I also injected 4 eyes with 300 μM doxorubicin only for
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control, and the result showed that red fluorescence was not due to the effect of
doxorubicin itself (Figure 12).
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Figure 11: Comparison of AAV-mediated transduction efficiency in the mouse retinas 1
month after being treated with AAV virus with or without proteasome inhibitors. (a-j)
whole-mount fluorescence images acquired at the INL without immunofluorescence
enhancement. (k-t) plot profiles of image a-j. The plot profile displays a two-dimensional
graph of the intensities of pixels along a random horizontal line across the image. The xaxis represents distance (in pixels) along the line, and the y-axis is the pixel intensity. (u)
comparison of fluorescence intensities of the mCherry-expressing retinal bipolar cells
treated with AAV virus with or without proteasome inhibitors. (v) cell densities of the retinal
bipolar cells that have an mCherry expression level above 0.05 RFU/pixel2. The data is
shown as mean ± SD. The n represents the number of retinas being examined. The
asterisk indicates statistically significant differences with *p<0.05, **p<0.01, ***p<0.001,
****p<0.0005 (one-way ANOVA).

Figure 12: whole-mount fluorescence image acquired at the INL in the retina 1 month
after being treated with 300 μM doxorubicin.

Table 2: Schedule of the one-time and two-time injection of 500 μM doxorubicin
Since doxorubicin was cleared from the retinas within 8 hours after intravitreal
injection in the rabbit eyes (Hu et al., 2007), I injected doxorubicin in the mouse eyes
twice with an 8-hour interval to examine its effect in improving AAV-mediated transduction
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efficiency in the retina (Table 2). There was no observable damage to the mouse eyes
with two injections with an 8-hour interval. The fluorescence intensity was increased by
32.4% and 43.1% after injection of 500 μM doxorubicin and after adding a booster dose
of 500 μM doxorubicin compared to the control (Figure 13a-c, g). There is no statistical
difference between the fluorescence intensity in retinas treated with one-time and twotime 500 μM doxorubicin (Figure 13g). Figure 13d-f are the plot profiles of Figure13a-c.
Figure13h shows the number of bipolar cells that have a mCherry expression level above
0.05 RFU/pixel2 within an image region of 0.0369 mm2 in retinas 1 month after being
treated with AAV virus alone, AAV with one-time 500 μM doxorubicin, and AAV with twotime 500 μM doxorubicin. The density of bipolar cells with a mCherry expression above
0.05 RFU/pixel2 in retinas treated with AAV with one-time 500 μM doxorubicin and AAV
with two-time 500 μM doxorubicin was 15.8 and 12.6 times higher than that in retinas
treated with AAV alone (Figure 13h). The two treatment groups have no statistical
difference with each other in terms of the bipolar cell density (Figure 13h).
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Figure 13: Comparison of AAV-mediated transduction efficiency in the mouse retinas 1
month after being treated with AAV virus with or without a booster dose of 500 μM
doxorubicin. (a-c) whole-mount fluorescence images acquired at the INL without
immunofluorescence enhancement. (d-f) plot profiles of image a-c. The plot profile
displays a two-dimensional graph of the intensities of pixels along a random horizontal
line across the image. The x-axis represents distance (in pixels) along the line, and the
y-axis is the pixel intensity. (g) comparison of fluorescence intensities of the mCherryexpressing retinal bipolar cells treated with AAV virus with or without a booster dose of
500 μM doxorubicin. (h) cell densities of the retinal bipolar cells that have an mCherry
expression level above 0.05 RFU/pixel2. The data is shown as mean ± SD. The n
represents the number of retinas being examined. The asterisk indicates statistically
significant differences with **p<0.01, ***p<0.001, ****p<0.0005 (one-way ANOVA).
Furthermore, I tested the effect of doxorubicin three months after virus injection. The
results showed that doxorubicin maintained its effect on enhancing the AAV transduction
efficiency in retinal bipolar cells in the 3-month duration in a dose dependent manner
(Figures 14a-d). At the concentration of 200 μM, 300 μM, and 500 μM, doxorubicin
increased the mCherry intensity by 25.8%, 40.2%, and 47.9%, respectively (Figure 14i).
Figures 14e-h represent the plot profiles of Figures 14a-d. Figure14j shows the number
of bipolar cells that have a mCherry expression level above 0.05 RFU/pixel2 within an
image region of 0.0369 mm2 in retinas 3 months after being treated with AAV virus with
or without different doses of doxorubicin. After co-administration of AAV virus with 300
μM and 500 μM doxorubicin, the density of bipolar cells with a mCherry expression above
0.05 RFU/pixel2 was 2.2 and 3.0 times higher than administration of AAV alone (Figure
14j).
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Figure 14. Comparison of AAV-mediated transduction efficiency in the mouse retinas 3
month after being treated with AAV virus with or without doxorubicin. (a-d) whole-mount
fluorescence images acquired at the INL without immunofluorescence enhancement. (eh) plot profiles of image a-d. The plot profile displays a two-dimensional graph of the
intensities of pixels along a random horizontal line across the image. The x-axis
represents distance (in pixels) along the line, and the y-axis is the pixel intensity. (i)
comparison of fluorescence intensities of the mCherry-expressing retinal bipolar cells
treated with AAV virus with or without doxorubicin. (j) cell densities of the retinal bipolar
cells that have an mCherry expression level above 0.05 RFU/pixel2. The data is shown
as mean ± SD. The n represents the number of retinas being examined. The asterisk
indicates statistically significant differences with **p<0.01, ***p<0.001, ****p<0.0005 (oneway ANOVA).
As stated above, doxorubicin can increase the number of bipolar cells that have a
high transgene expression level. However, whether doxorubicin could affect the number
of all the AAV-transduced bipolar cells is unknown. Therefore, I counted all the
transduced bipolar cells within an image region of 0.0369 mm2 in retinas 1 month and 3
months after being treated with AAV virus with or without different doses of doxorubicin.
To better display all the mCherry-expressing bipolar cells, the retinas were
immunostained with antibody against mCherry (images are not shown). The results show
that the application of doxorubicin did not alter the density of the transduced bipolar cells
(Figure 15a-b).
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Figure 15. Comparison of bipolar cell densities in the mouse retinas 1 month and 3
months after being treated with AAV virus with or without doxorubicin. (a) comparison of
AAV-transduced bipolar cell densities in the mouse retinas 1 month after being treated
with AAV virus with or without doxorubicin. (b) comparison of AAV-transduced bipolar cell
densities in the mouse retinas 3 months after being treated with AAV virus with or without
doxorubicin. The data is shown as mean ± SD. The n represents the number of retinas
being examined. The transduced bipolar cells with mCherry expression were
immunostained with antibody against mCherry before counting.
2.5 Discussion
In this study, I evaluated the effect of three proteasome inhibitors, doxorubicin,
aclarubicin and MG132 on AAV-mediated transduction efficiency in retinal bipolar cells in
mice. Consistent with previous studies performed both in non-neuronal cells as well as in
neuronal cells in vitro and in vivo (Yan et al., 2004; Zhang et al., 2009a), my results show
that doxorubicin can also enhance AAV-mediated transduction efficiency in retinal bipolar
cells in vivo (Figure 11u). Thus, this study suggests the potential value for the use of
doxorubicin for facilitating the AAV-mediated transduction efficiency in retinal gene
therapy. On the other hand, surprisingly, I failed to observe such an effect for aclarubicin
and MG132 in retinal bipolar cells (Figure 11u) although both aclarubicin and MG132
were reported to augment AAV2 transduction in non-neuronal cells. However, it should
be noted that neither aclarubicin nor MG-132 have been previously evaluated in neuronal
cells. Therefore, the lack of effect of aclarubicin and MG132 could be due to a difference
between neuronal and non-neuronal cells. It might also be due to a drug metabolism issue
in the mouse eye. Further studies would be interesting to investigate the underlying
mechanism for such a discrepancy.
Although the dose-dependent effect of doxorubicin was reported in neuronal cell lines
and primary neuron cultures (Zhang et al., 2009a), in this study I examined the dosedependent effect of doxorubicin in retinal neurons in vivo. My results show that the ability
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of doxorubicin to enhance the AAV transgene expression in retinal bipolar cells appears
to be both dose-dependent and time-dependent. Specifically, the transgene expression
level peaked at the concentration of 300 μM in the short-term (1 month after treatment)
and 300-500 μM in the long-term (3 months after treatment) (Figure 11u and 14i). The
mCherry expression level in retinas treated with AAV alone or with 200 μM or 500 μM
doxorubicin 3 months after injection was increased compared with that in retinas treated
with same regimen 1 month after injection; while the mCherry expression level in retinas
treated with 300 μM doxorubicin had no significant difference between 1 month and 3
months after virus injection (Figure 11u and 14i). It is likely that the AAV transgene
expression in retinal bipolar cells did not reach its maximum level 1 month after viral
delivery, which explains that in the control group (AAV alone), the mCherry expression
level 3 months after injection was higher than 1 month after injection. Since there is no
statistic difference between the mCherry intensities in retinas treated with 300 μM and
500 μM doxorubicin 3 months after virus injection (Figure 14i), suggesting that the effect
of doxorubicin has reached the maximum level; the lack of increase in mCherry intensity
in retinas treated with 300 μM doxorubicin from 1 month to 3 months after virus injection
might be due to the effect of doxorubicin already reached the maximum level 1 month
after virus injection.
Figures 11k-o and Figures 14e-h are the plot profiles of Figures11a-e and
Figures14a-d, respectively. The single cells that represent the maximum mCherry
expression level in each group treated with AAV with or without doxorubicin actually
displayed similar pixel intensities (Figures 11k-o, Figures 14e-h). Consistent with the
mean fluorescence intensities (Figure 11u, Figure 14i), the density of bipolar cells with a
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mCherry expression above 0.05 RFU/pixel2 was increased in retinas treated with 300 μM,
500 μM, and 800 μM doxorubicin 1 month after virus injection (Figure 11v), and was
increased in retinas treated with 300 μM and 500 μM doxorubicin 3 months after virus
injection (Figure 14j). These results suggest that doxorubicin increased the AAV
transduction efficiency in retinal bipolar cells by increasing the number of cells that are
able to reach high transgene expression level. Moreover, Figure 15 showed that
application of doxorubicin did not alter the density of the AAV-transduced bipolar cells 1
month and 3 months after virus injection. Together, my results indicate that doxorubicin
increased AAV transduction efficiency not by increasing the number of cells transduced
by AAV virus, but by increasing transgene expression in the transduced bipolar cells.
These results are consistent with the working mechanism of doxorubicin, which facilitates
the AAV virus intracellular trafficking process, while has no effect in changing the AAV
virus cell entry process.
In conclusion, my results indicate that doxorubicin but not aclarubicin and MG132 is
effective in enhancing AAV transduction efficiency in retinal bipolar cells in mice. Since
doxorubicin is a proteasome inhibitor that blocks the intracellular degradation of virus
vectors, my experimental results validate my hypothesis that virus degradation during
intracellular trafficking is one of major limiting factors for the low AAV transduction
efficiency in retinal bipolar cells.
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CHAPTER 3. EVALUATION OF THE DOXORUBICIN-INDUCED TOXICITY TO THE
MOUSE EYES
3.1 Hypothesis
Doxorubicin-mediated free radical generation would cause toxicity to the mouse
retina and lens following intravitreal injection.
3.2 Rationale
Doxorubicin was previously reported to induce neurotoxicity to rat cortical neurons
(Lopes et al., 2008). One mechanism of doxorubicin-induced cell damage is the formation
of the drug-iron complex which catalyzes the formation of hydroxyl radical and causes
DNA damage (Muindi et al., 1984). Dexrazoxane (Zinecard) is a FDA-approved drug that
is used to reduce the anthracycline-induced cytotoxicity. The active form of dexrazoxane
is similar to EDTA, which chelates iron and limits the formation of anthracycline-iron
complexes, and therefore reduces the generation of free radicals and the subsequent
oxidative damage to cells (Ichikawa et al., 2014; Langer, 2014). Therefore, I also tested
the short-term and long-term cytotoxicity that doxorubicin induced in the retina, as well as
the antidote effect of dexrazoxane on retinal neurons treated with doxorubicin.
3.3 Experimental design and method
Animals and materials
Described in chapter 2.2 except the following. Dexrazoxane was purchased from
Abcam, Cambridge, MA.
Virus injection
Described in chapter 2.2 except the following. The injection solution preparation
containing AAV virus, doxorubicin, and dexrazoxane is listed in Table 3.
Immunohistochemistry
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Described in chapter 2.2 except the following. The primary antibodies used in this
study were: goat anti-mCherry (1:2000; Biorbyt, Cambridge, UK), mouse anti-PKC (1:500;
Santa Cruz, Dallas, Texas, USA). The secondary antibodies were conjugated to Alexa
555 (1:1000), or Alexa 488 (1:500). The primary antibodies were diluted in the same
solution and applied for two days at room temperature (RT). The retinas were then
washed several times, followed by incubation in the secondary antibodies for one day at
RT. Nuclei were stained with DAPI (1: 2.8ml; Sigma-Aldrich, St. Louis, MO); the retinas
were incubated for 30 min in the DAPI solution.
For immunostaining of retinal vertical sections, the retinas were cryoprotected in
graded sucrose (10%, 20%, and 30% wt/vol, respectively, in PB) and cut at 16 μm. The
following primary antibodies were used in this study: goat anti-mCherry (1:2000; Biorbyt,
Cambridge, UK), mouse anti-PKC (1:500; Santa Cruz, Dallas, Texas, USA). The
secondary antibodies were conjugated to Alexa 555 (1:1000), or Alexa 488 (1:500). The
retinal sections were incubated for 1 hr in the block solution. The primary antibodies were
diluted in the same solution and applied overnight at RT, followed by incubation for 2 hrs
in the secondary antibodies. Nuclei were stained with DAPI (1: 2.8ml; Sigma-Aldrich, St.
Louis, MO); the retinal sections were incubated for 3 min in the DAPI solution.
Quantitative fluorescence and cell density measurements
Described in chapter 2.2. For measurement of the cell density, 12 images (at 20X
magnification) were taken evenly throughout each retina at the ganglion cell layer (GCL).
The cell density at the GCL was compared as the mean ± SD of the cell number within
an image region of 0.1476 mm² (at 20X magnification).
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Table 3: Preparation of the injection solutions containing AAV virus, doxorubicin, and
dexrazoxane.
3.4 Results
3.4.1 Higher doses of doxorubicin lead to long-term cytotoxicity in the retina
Previous studies reported that doxorubicin could induce neurotoxicity to rat cortical
neurons (Lopes et al., 2008). Therefore, I went on to examine whether the co-application
of doxorubicin could produce cytotoxicity to the retinal neurons. I first evaluated the dosedependent effect of doxorubicin on the survival of the cells at the GCL by measuring their
density one and three months after co-injection of AAV2 virus vectors and doxorubicin.
My results showed that the density of the cells as labeled by DAPI remained unchanged
1 month after virus injection with doxorubicin treatment (Figure 16), but decreased by
28.5% and 29.9% 3 months after the treatment with 300 and 500 doxorubicin, respectively
(Figure 17).
I also evaluated the effect of doxorubicin and its potential toxicity to other retinal
neurons by measuring the thickness of the outer nuclear layer (ONL) and the inner
nuclear layer (INL) together with the inner plexiform layer (IPL) 3 months after doxorubicin
treatment. For this purpose, the retinas were stained with DAPI (blue color) and rod
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bipolar cells were labeled with antibody against PKC (green color). My results show that
the thickness of the ONL did not change significantly (Figure 18a-e). In contrast, the
thickness of the INL+IPL decreased by 19.0% and 30.8% 3 months after exposure to 300
and 500 μM doxorubicin, respectively (Figure 18a-d, and f). The thickness of the INL+IPL
in retinas exposed to 500 μM doxorubicin decreased by 14.5% compared with those
exposed to 300 μM doxorubicin (Figure 18f). Together, these results indicate that
doxorubicin at higher concentrations (≥300 µM) is toxic to inner retinal neurons in the long
term.

Figure 16. Comparison of the cell densities in the GCL 1 month after being treated with
AAV virus with or without doxorubicin. (a-d) whole-mount images acquired at the GCL
with DAPI staining. (e) comparison of cell densities in the mouse retinal GCL 1 month
after being treated with AAV virus with or without doxorubicin. The data is shown as mean
± SD. The n represents the number of retinas being examined.
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Figure 17. Comparison of the cell densities in the GCL 3 months after being treated with
AAV virus with or without doxorubicin. (a-d) whole-mount images acquired at the GCL
with DAPI staining. (e) comparison of cell densities in the mouse retinal GCL 3 months
after being treated with AAV virus with or without doxorubicin. The data is shown as mean
± SD. The n represents the number of retinas being examined. The asterisk indicates
statistically significant differences with **p<0.01 (one-way ANOVA).
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Figure 18. Comparison of ONL and INL+IPL thickness in the mouse retinas 3 months
after being treated with AAV virus with or without doxorubicin. (a-d) retinal vertical
sections with DAPI staining and immunostaining with antibodies against mCherry and
PKC. (e) comparison of ONL thickness and (f) INL+IPL thickness in the mouse retinas 3
months after being treated with AAV virus with or without doxorubicin. The data is shown
as mean ± SD. The n represents the number of retinas being examined. The asterisk
indicates statistically significant differences with ****p<0.0005 (one-way ANOVA). ONL:
outer nuclear layer; INL: inner nuclear layer; IPL: inner plexiform layer; GCL: ganglion cell
layer.
3.4.2 Co-administration of dexrazoxane and doxorubicin prevented the doxorubicininduced neurotoxicity
Next, I went on to examine the possible effect of dexrazoxane against the
doxorubicin-induced neurotoxicity in retinal neurons. For this purpose, AAV vectors were
co-injected with doxorubicin and dexrazoxane. The dosage ratio of dexrazoxane to
doxorubicin is 10:1, as suggested by the previous studies in mice (Imondi et al., 1996).
AAV vectors co-injected with dexrazoxane served as control. My results show that the
cell density of the GCL was not changed 1 month after co-injection of AAV and
dexrazoxane with or without doxorubicin (Figure 19). However, there was a slight
decrease (15.7%) in the cell density 3 months after co-injection of AAV and dexrazoxane
with 500 μM doxorubicin (Figure 20). The thickness of the ONL and the INL+IPL remained
unchanged 3 months after the co-administration of dexrazoxane (Figure 21). Additionally,
there was no statistical difference in terms of the cell density of the GCL and the thickness
of the ONL and the INL+IPL between retinas treated with AAV vectors alone and those
co-administered with dexrazoxane (Figure 16-21). Together, these results indicate that
the doxorubicin-mediated cytotoxicity was mitigated by dexrazoxane.
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Figure 19. Comparison of the cell densities in the GCL 1 month after being treated with
AAV virus and dexrazoxane with or without doxorubicin. (a-d) whole-mount images
acquired at the GCL with DAPI staining. (e) comparison of cell densities in the mouse
retinal GCL 1 month after being treated with AAV virus and dexrazoxane with or without
doxorubicin. The data is shown as mean ± SD. The n represents the number of retinas
being examined.

Figure 20. Comparison of the cell densities in the GCL 3 months after being treated with
AAV virus and dexrazoxane with or without doxorubicin. (a-d) whole-mount images
acquired at the GCL with DAPI staining. (e) comparison of cell densities in the mouse
retinal GCL 3 months after being treated with AAV virus and dexrazoxane with or without
doxorubicin. The data is shown as mean ± SD. The n represents the number of retinas
being examined. The asterisk indicates statistically significant differences with *p<0.05
(one-way ANOVA).
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Figure 21. Comparison of ONL and INL+IPL thickness in the mouse retinas 3 months
after being treated with AAV virus and dexrazoxane with or without doxorubicin. (a-d)
retinal vertical sections with DAPI staining and immunostaining with antibodies against
mCherry and PKC. (e) comparison of ONL thickness and (f) INL+IPL thickness in the
mouse retinas 3 months after being treated with AAV virus and dexrazoxane with or
without doxorubicin. The data is shown as mean ± SD. The n represents the number of
retinas being examined. ONL: outer nuclear layer; INL: inner nuclear layer; IPL: inner
plexiform layer; GCL: ganglion cell layer.
3.4.3 Co-administration of dexrazoxane and doxorubicin improves AAV-mediated
mCherry expression
I then examined whether doxorubicin co-administered with dexrazoxane can still
improve AAV-mediated transduction efficiency in bipolar cells. Again, the expression of
mCherry was examined 1 month and 3 months after virus injection (Figure 22-23). The
mCherry expression level in retinas treated with 200 μM, 300 μM, and 500 μM doxorubicin
together with dexrazoxane was increased by 24.3%, 19.4%, and 18.9% 1 month after
injection, and 48.3%, 55.1%, and 38.9% 3 months after injection, compared to that in
retinas treated with dexrazoxane (Figure 22i and 23i). Interestingly, compared with
injection of AAV alone, co-administration of AAV and dexrazoxane was shown to increase
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mCherry expression level by 25.55% 1 month after injection (Figures 11u and 22i), while
decrease mCherry expression level by 13.7% 3 months after injection (Figures 14i and
23i). Importantly, however, compared to that in retinas treated with AAV alone, the
mCherry expression with the application of 200 μM, 300 μM, and 500 μM doxorubicin
together with dexrazoxane was still increased by 56.1%, 49.85, and 49.26 1 month after
injection, and increased by 27.9%, 33.8%, and 19.9% 3 months after injection (Figures
11u, 14i, 22i, and 23i). Another noticeable thing is that 3 months after co-injection of AAV
and 500 μM doxorubicin together with dexrazoxane decreased the mCherry expression
level by 19.0% compared with the regimen without dexrazoxane (Figures 14i and 23i).
Figures 22e-h and 23e-h represent the plot profiles of Figure 22a-d and 23a-d.
Figures 22j and 23j show the number of bipolar cells that have a mCherry expression
level above 0.05 RFU/pixel2 within an image region of 0.0369 mm2 in retinas 1 month
and 3 months after being treated with AAV virus and dexrazoxane with or without different
doses of doxorubicin. 1 month after co-administration of AAV virus and dexrazoxane with
200 μM and 500 μM doxorubicin, the density of bipolar cells with a mCherry expression
above 0.05 RFU/pixel2 was 7.2 and 6.0 times higher than administration of AAV with
dexrazoxane (Figure 22j); again, the result was not compared with that treated with AAV
alone. 3 months after co-administration of AAV virus and dexrazoxane with 200 μM and
300 μM doxorubicin, the density of bipolar cells with a mCherry expression above 0.05
RFU/pixel2 was 5.0 and 7.2 times higher than administration of AAV with dexrazoxane; 3
months after co-administration of AAV virus and dexrazoxane with 500 μM doxorubicin,
the density of bipolar cells with a mCherry expression above 0.05 RFU/pixel2 was 1.2
times higher than administration of AAV alone (Figure 23j). Also, consistent with the
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mCherry expression level, 3 months after co-administration of AAV and dexrazoxane was
shown to decrease the density of bipolar cells with a mCherry expression above 0.05
RFU/pixel2 compared with injection of AAV alone (Figure 23j).
To make sure that co-administration of dexrazoxane and doxorubicin would not
change the number of AAV-transduced bipolar cells. I counted all the transduced bipolar
cells within an image region of 0.0369 mm2 in retinas 1 month and 3 months after being
treated with AAV virus and dexrazoxane with or without different doses of doxorubicin.
To better display all the mCherry-expressing bipolar cells, the retinas were
immunostained with antibody against mCherry (images are not shown). The results show
that the application of doxorubicin and dexrazoxane did not alter the density of the
transduced bipolar cells (Figure 24a-b).

55

56
Figure 22. Comparison of AAV-mediated transduction efficiency in the mouse retinas 1
month after being treated with AAV virus and dexrazoxane with or without doxorubicin.
(a-d) whole-mount fluorescence images acquired at the INL without immunofluorescence
enhancement. (e-h) plot profiles of image a-d. The plot profile displays a two-dimensional
graph of the intensities of pixels along a random horizontal line across the image. The xaxis represents distance (in pixels) along the line, and the y-axis is the pixel intensity. (i)
comparison of fluorescence intensities of the mCherry-expressing retinal bipolar cells
treated with AAV virus and dexrazoxane with or without doxorubicin. (j) cell densities of
the retinal bipolar cells that have an mCherry expression level above 0.05 RFU/pixel2.
The data is shown as mean ± SD. The n represents the number of retinas being examined.
The asterisk indicates statistically significant differences with *p<0.05, **p<0.01,
***p<0.001 (one-way ANOVA).
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Figure 23. Comparison of AAV-mediated transduction efficiency in the mouse retinas 3
months after being treated with AAV virus and dexrazoxane with or without doxorubicin.
(a-d) whole-mount fluorescence images acquired at the INL without immunofluorescence
enhancement. (e-h) plot profiles of image a-d. The plot profile displays a two-dimensional
graph of the intensities of pixels along a random horizontal line across the image. The xaxis represents distance (in pixels) along the line, and the y-axis is the pixel intensity. (i)
comparison of fluorescence intensities of the mCherry-expressing retinal bipolar cells
treated with AAV virus and dexrazoxane with or without doxorubicin. (j) cell densities of
the retinal bipolar cells that have an mCherry expression level above 0.05 RFU/pixel2.
The data is shown as mean ± SD. The n represents the number of retinas being examined.
The asterisk indicates statistically significant differences with **p<0.01, ****p<0.0005
(one-way ANOVA).

Figure 24. Comparison of bipolar cell densities in the mouse retinas 1 month and 3
months after being treated with AAV virus and dexrazoxane with or without doxorubicin.
(a) comparison of AAV-transduced bipolar cell densities in the mouse retinas 1 month
after being treated with AAV virus and dexrazoxane with or without doxorubicin. (b)
comparison of AAV-transduced bipolar cell densities in the mouse retinas 3 months after
being treated with AAV virus and dexrazoxane with or without doxorubicin. The data is
shown as mean ± SD. The n represents the number of retinas being examined. The
transduced bipolar cells with mCherry expression were immunostained with antibody
against mCherry before counting.
3.4.4 Intravitreal injection of doxorubicin caused lens opacity in the mouse eyes
Previous research reported that intravitreal injection of doxorubicin in rabbit eyes
could cause lens cataract within 2-3 months (Phylactos and Unger, 1998). To investigate
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whether intravitreal injection of doxorubicin would cause lens cataract in our mouse model,
I observed the mouse lens 1 month and 3 months after injection of virus with or without
doxorubicin. At the end of one month following intravitreal injection of high-dose
doxorubicin (500 μM), lens opacity in three out of eight mouse eyes was observed (Table
4), which started to appear around 1-2 weeks after intravitreal injection. At the end of
three months following intravitreal injection, even lower doses of doxorubicin started to
show lens opacity. Two out of eight mouse eyes injected with 200 μM doxorubicin
appeared to have mild lens opacity, while five out of eight and nine out of ten mouse eyes
injected with 300 μM and 500 μM doxorubicin showed mature lens opacity, respectively
(Table 4). The slit lamp image of the lens opacity is shown in Figure 25. Since the
mechanism of doxorubicin-induced cataract is due to the generation of oxygen radicals
(Phylactos and Unger, 1998), and dexrazoxane was reported to reduce the production of
free radicals by doxorubicin-iron complex (Langer, 2014), co-injection of doxorubicin and
dexrazoxane could possibly alleviate doxorubicin-induced lens cataract. My results
showed that with co-administration of dexrazoxane, three out of eight mouse eyes
showed lens opacity 1 month after treatment of 500 μM doxorubicin; six out of eight
mouse eyes showed lens opacity 3 months after treatment of 500 μM doxorubicin, and
the mouse eyes treated with 200 μM and 300 μM doxorubicin did not have lens opacity
at all 3 months after injection (Table 4).
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Figure 25. Slit lamp image of the mouse eye 3 months after being treated with high
concentration of doxorubicin.

Table 4: Number of mouse eyes with lens opacity 1 month and 3 months after being
treated with AAV virus with or without doxorubicin and dexrazoxane.
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3.5 Discussion
Since doxorubicin was reported to induce neurotoxicity (Lopes et al., 2008), I
evaluated both the short-term (1 month after treatment) and the long-term (3 months after
treatment) doxorubicin-induced cytotoxicity in the mouse retina. I found that doxorubicin
at a relatively high concentration (300 – 500 μM) could lead to cytotoxicity to retinal
neurons in the long term. The cytotoxic effects include reducing the cell density of the
GCL and the thickness of the INL and IPL. Since the INL of the mouse retina contains
bipolar cells, amacrine cells, horizontal cells, and Muller cells (Jeon et al., 1998), and the
cell density of bipolar cells did not change 3 months after injection of high-dose (500 μM)
doxorubicin (Figure 15b), the thinning of the INL together with the IPL is likely due to the
loss of the other types of cells. In harlequin (Hq) mutant mice (a mouse model with
oxidative stress-mediated neurodegeneration), retinal ganglion cells, horizontal cells, and
amacrine cells were found to be positive for 8-OHdG (8-hydroxydeoxyguanosine, a
principal component of oxidatively damaged DNA) (Klein et al., 2002), which suggested
the susceptibilities of those cell types to oxidative damage. A possible reason could be
the expression of different subsets of UPS (ubiquitin proteasome system) components
among different retinal cell types (Plafker et al., 2012). The susceptibilities of horizontal
cells and amacrine cells to oxidative damage may explain the decreased thickness of the
INL and IPL. Interestingly, no apparent cell loss was observed for photoreceptors
because the thickness of the ONL was not found to be altered after the treatment with
doxorubicin. Photoreceptor cells are located farther from the injection site, thus less
exposed to the doxorubicin. Moreover, they were not found to be positive for 8-OHdG
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(Klein et al., 2002), therefore might be less susceptible to the doxorubicin-induced
oxidative damage.
The late-onset doxorubicin-induced cytotoxicity has been reported in cardiac tissue
when doxorubicin was used as an antitumor drug clinically (Kumar et al., 2012; Steinherz
et al., 1991). The mechanism of causing cell death could be due to the fact that
doxorubicin-induced reactive oxygen species (ROS) formation mutates the mitochondria
DNA and damages the membrane lipid structure and respiratory chain proteins (Singal
and Iliskovic, 1998). The mitochondrial injury after acute doxorubicin exposure then
accumulates over time without further doxorubicin exposure, which is also referred to as
“dose memory”(Lebrecht et al., 2003).
Dexrazoxane (Zinecard) is a FDA-approved drug that has been used to reduce
anthracycline (doxorubicin)-induced cytotoxicity. Our results show that co-injection of
dexrazoxane with doxorubicin can mitigate the doxorubicin-induced cytotoxicity, while still
maintaining the effect of doxorubicin. Under our experimental conditions, the optimal dose
of doxorubicin if used in combination with dexrazoxane is 200-300 μM, as it showed no
long-term neurotoxicity (Figure 20 and 21) and the AAV-mediated transgene expression
in bipolar cells was significantly improved (Figure 23). On the other hand, there was no
statistically significant difference in the cell density of the GCL between retinas treated
with 500 μM doxorubicin with/without co-administration of dexrazoxane (Figure 17 and
20). This suggests that co-administration of dexrazoxane could not completely abrogate
the doxorubicin-induced cytotoxicity, especially when the dose of doxorubicin was high.
Consistent with the results in clinic, dexrazoxane does not completely eliminate the risk
of doxorubicin-induced cardiotoxicity(Hensley et al., 2009). There was no statistically
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significant difference in the mCherry intensity among retinas treated with 200 μM, 300 μM,
and 500 μM doxorubicin and dexrazoxane after virus injection (Figure 23). When
comparing the mCherry expression level between retinas treated with 200-500 μM
doxorubicin with and without dexrazoxane, we found that there was a decrease in retinas
treated with 500 μM doxorubicin and dexrazoxane compared to those without
dexrazoxane (Figure 14 and Figure 23). This is possibly because the anti-ROS effect of
dexrazoxane might also reduce part of the efficacy of doxorubicin, since ROS has been
reported to augment AAV transduction efficiency (Sanlioglu and Engelhardt, 1999). We
also observed a slight decrease in the mCherry expression level in retinas treated with
AAV and dexrazoxane compared to retinas treated with AAV alone (Figure 23).
Currently, the application of dexrazoxane is limited in reducing doxorubicin-induced
cytotoxicity. However, dexrazoxane is also a mammalian DNA topoisomerase II inhibitor
(Hasinoff et al., 1995). The adverse effects of dexrazoxane when used intravenously
include myelosuppression, secondary malignancies, and embryo-fetal toxicity (Hensley
et al., 2009). However, since the retinal neurons are non-dividing cells, it is less likely for
dexrazoxane to affect normal cell function as a DNA topoisomerase II inhibitor.
Furthermore, no known research has evaluated the effect of dexrazoxane on AAV
transduction. Further studies need to be done to determine whether the iron-chelating
effect or any other possible effects of dexrazoxane could interrupt AAV transduction.
It is worth pointing out that, in clinical practice, dexrazoxane is only used when
patients received a cumulative doxorubicin dose of 300 mg/m2; it is not used
concomitantly with the initial doses of doxorubicin to avoid interfering with the anticancer
effect of doxorubicin (Hensley et al., 2009; Swain et al., 1997a). In addition, dexrazoxane
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is given before the administration of doxorubicin (within 30 minutes) (Hensley et al., 2009).
Since the higher doses of doxorubicin were shown to cause toxicity to the retina and we
only did a one-time intravitreal injection, it would make it necessary for the concomitant
use of dexrazoxane. Therefore, in this study we delivered the two drugs together with the
AAV virus via co-injection. Certainly, further studies on the pharmacodynamics and
pharmacokinetics of the two drugs in the eye may help to develop an optimal protocol for
drug delivery for clinical applications.
It was reported that intravitreal injection of doxorubicin in rabbit eyes could cause
lens cataract within 2-3 months; the underlying mechanism is due to the oxygen radicals
generated from doxorubicin (Phylactos and Unger, 1998). Cataractogenesis was reported
even when doxorubicin was given intraperitoneally in rats, with the histopathologic
findings showing nuclei retention in the central lens fibers and cortical lens fiber-cell
swelling with liquefaction (Bayer et al., 2005). My results showed that three out of eight
mouse eyes were observed to have cataract at the end of one month following intravitreal
injection of high-dose doxorubicin (500 μM). At the end of three months following
intravitreal injection, two out of eight mouse eyes treated with 200 μM doxorubicin were
observed to have mild lens opacity, five out of eight mouse eyes treated with 300 μM
doxorubicin and nine out of ten mouse eyes treated with 500 μM doxorubicin showed
mature lens opacity, respectively (Table 4). With co-administration of dexrazoxane, three
out of eight mouse eyes showed lens opacity 1 month after treatment with 500 μM
doxorubicin; six out of eight mouse eyes showed lens opacity 3 months after treatment
with 500 μM doxorubicin, and the mouse eyes treated with 200 μM and 300 μM
doxorubicin did not have lens opacity at all 3 months after injection (Table 4). According
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to my results on the long-term (3 months) effect of doxorubicin and dexrazoxane on the
mouse lens, the lens cataracts caused by intravitreal injection of lower doses of
doxorubicin (200 μM and 300 μM) could be totally prevented by co-injection of doxorubicin
and dexrazoxane; while the incidence of lens cataracts caused by intravitreal injection of
high dose doxorubicin (500 μM doxorubicin) was reduced, with the ratio of number of lens
cataracts/total number of mouse eyes decreased from 9/10 to 6/8. This indicated that
doxorubicin-induced lens cataracts in the mouse eyes after intravitreal injection could be
due to the generation of oxygen radicals, and that with the addition of an oxygen radical
reducing drug (dexrazoxane), the incidence of lens cataracts was markedly reduced.
In conclusion, my results suggest that the co-application of doxorubicin and
dexrazoxane could be a potential adjuvant regimen to AAV-mediated gene therapy.
Further studies on the mechanism of doxorubicin and dexrazoxane interaction may help
to further improve the regimen to keep the effect of facilitating AAV transduction while
simultaneously reducing the toxicity to both the retinas and the lenses.
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CHAPTER 4: TO TEST THE HYPOTHESIS THAT ILM ACTS AS A BARRIER FOR AAV
TRANSDUCTION IN RETINAL BIPOLAR CELLS
4.1 Hypothesis
Enzymatic digestion of inner limiting membrane would increase the number of AAVtransduced retinal neurons.
4.2 Rationale
The bipolar cell layer is located in the middle of the retina, which means that it is
difficult for viruses to access bipolar cells with either intravitreal or subretinal delivery. For
our purpose, we prefer to inject virus through the vitreous space; hence a second barrier
shows up: the inner limiting membrane. The inner limiting membrane (ILM) is a basement
membrane that resides between the vitreous body and the retina as a boundary. Removal
of ILM would allow more AAV virus to access to the retinal neurons. Therefore, enzymatic
digestion of the ILM may increase the number of retinal neurons transduced by AAV virus.
Plasmin is a trypsin-like serine protease; it can dissolve laminin and fibronectin in ILM, as
well as facilitate extracellular matrix degradation (Liotta et al., 1981). In this study, I coinjected AAV2 virus with different doses of plasmin to evaluate the effect of plasmin on
improving AAV transduction efficiency in the retinal bipolar cells.
4.3 Experimental design and method
Animals and materials
Described in chapter 2.2 except the following. Plasmin was purchased from SigmaAldrich (St. Louis, MO, USA).
Virus injection
Described in chapter 2.2 except the following. The plasmin injection solutions are
listed in Table 5.
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Quantitative fluorescence and cell density measurements
Described in chapter 2.2.

Table 5. The preparation of plasmin injection solutions. H, high concentration; M, middle
concentration; L, low concentration.
4.4 Results
My results showed that injection of different concentrations of plasmin with AAV virus
did not improve the AAV-mediated mCherry expression in the retinal bipolar cells
throughout the retina, including the center region (Figure 26a-d, i), middle region (Figure
27a-d, i), and peripheral retinal region (Figure 28a-d, i). Figure 26e-h and, 27e-h, and
28e-h represent the plot profiles of Figure 26a-d, 27a-d, and 28a-d. Figure26j, 27j, and
28j show the number of bipolar cells that have a mCherry expression level above 0.05
RFU/pixel2 within an image region of 0.0369 mm2 in center, middle, and peripheral retina.
The result is consistent with the mCherry expression level.
In terms of the density of all the AAV-transduced bipolar cells, injection of middle
concentration of plasmin increased the cell density in the center area of the retina (Figure
29a), and injection of both low and middle concentration of plasmin increased the cell
density in the middle area of the retina (Figure 29b). While in the peripheral area of the
retina, high concentration of plasmin actually decreased the cell density (Figure 29c).
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Figure 26. Comparison of AAV-mediated transduction efficiency and bipolar cell densities
in the center area of the mouse retinas 1 month after being treated with AAV virus with or
without plasmin. (a-d) whole-mount fluorescence images acquired at the INL without
immunofluorescence enhancement. (e-h) plot profiles of image a-d. The plot profile
displays a two-dimensional graph of the intensities of pixels along a random horizontal
line across the image. The x-axis represents distance (in pixels) along the line, and the
y-axis is the pixel intensity. (i) comparison of fluorescence intensities of the mCherryexpressing retinal bipolar cells treated with AAV virus with or without plasmin. (j) cell
densities of the retinal bipolar cells that have an mCherry expression level above 0.05
RFU/pixel2. The data is shown as mean ± SD. The n represents the number of retinas
being examined.
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Figure 27. Comparison of AAV-mediated transduction efficiency and bipolar cell densities
in the middle area of the mouse retinas 1 month after being treated with AAV virus with
or without plasmin. (a-d) whole-mount fluorescence images acquired at the INL without
immunofluorescence enhancement. (e-h) plot profiles of image a-d. The plot profile
displays a two-dimensional graph of the intensities of pixels along a random horizontal
line across the image. The x-axis represents distance (in pixels) along the line, and the
y-axis is the pixel intensity. (i) comparison of fluorescence intensities of the mCherryexpressing retinal bipolar cells treated with AAV virus with or without plasmin. (j) cell
densities of the retinal bipolar cells that have an mCherry expression level above 0.05
RFU/pixel2. The data is shown as mean ± SD. The n represents the number of retinas
being examined.
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Figure 28. Comparison of AAV-mediated transduction efficiency and bipolar cell densities
in the peripheral area of the mouse retinas 1 month after being treated with AAV virus
with or without plasmin. (a-d) whole-mount fluorescence images acquired at the INL
without immunofluorescence enhancement. (e-h) plot profiles of image a-d. The plot
profile displays a two-dimensional graph of the intensities of pixels along a random
horizontal line across the image. The x-axis represents distance (in pixels) along the line,
and the y-axis is the pixel intensity. (i) comparison of fluorescence intensities of the
mCherry-expressing retinal bipolar cells treated with AAV virus with or without plasmin.
(j) cell densities of the retinal bipolar cells that have an mCherry expression level above
0.05 RFU/pixel2. The data is shown as mean ± SD. The n represents the number of retinas
being examined.

Figure 29. Comparison of bipolar cell densities in the center/middle/peripheral area of the
mouse retinas 1 month after being treated with AAV virus with or without plasmin. (a)
comparison of AAV-transduced bipolar cell densities in the center area of the mouse
retinas. (b) comparison of AAV-transduced bipolar cell densities in the middle area of the
mouse retinas. (c) comparison of AAV-transduced bipolar cell densities in the peripheral
area of the mouse retinas. The data is shown as mean ± SD. The n represents the number
of retinas being examined. The asterisk indicates statistically significant differences with
*p<0.05, **p<0.01, ***p<0.001 (one-way ANOVA).
4.5 Discussion
There are mainly two ways to remove the ILM. One method is enzyme digestion, the
other is direct surgical removal. Previous research has reported that intravitreal AAVmediated gene transduction in the inner retina was improved by surgical peeling of the
ILM in cynomolgus monkeys (Takahashi et al., 2017). However, damage of the Muller
cell processes following the surgical removal of the ILM was revealed (Nakamura et al.,
2003). Therefore, we investigated using enzyme digestion.
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In this study, I examined the effect of 3 different doses of plasmin in improving AAV
transduction efficiency in the retinal bipolar cells. My results showed no improvement in
AAV-mediated mCherry expression level in the retina after intravitreal injection of AAV2
virus and plasmin. However, the density of all the AAV-transduced retinal bipolar cells
was increased in the center and middle area of the retina following co-injection of AAV2
virus and middle and/or low concentration of plasmin.
Previous research reported that intravitreal co-injection of AAV5 with a proteolytic
enzyme Pronase E leads to a marked enhancement of AAV5 transduction in various
retinal cell types in rats. They also found that in contrast to AAV2, AAV5 did not have
attachment sites at the vitreoretinal junction. Enzymatic digestion of the ILM removed the
barrier for the AAV serotype 5 to reach the retina (Dalkara et al., 2009a). The primary
receptors for different AAV serotypes are different. AAV5 requires a terminal sialic acid
for binding and transduction (Kaludov et al., 2001), while AAV2 uses HSPG (Summerford
and Samulski, 1998b). Since sialic acid is absent in the ILM (Cho et al., 2002), sialic aciddependent AAV serotype 5 is unable to accumulate at the vitreoretinal junction (Dalkara
et al., 2009b) and thus can possibly explain the lack of transduction efficiency of AAV5
virus vectors following intravitreal injection (Hellström et al., 2008).

AAV2 virus, in

contrast, is the most efficient one among other serotypes of AAV virus after intravitreal
injection (Hellström et al., 2008). Therefore, removal of the ILM may have a much stronger
influence on the AAV5 transduction efficiency in the retina compared to the AAV2
transduction efficiency. As indicated in my results, enzymatic digestion of the ILM by
plasmin did not make a difference on the AAV2 transduction efficiency in the retina
following intravitreal injection. Another enzyme, microplasmin, has been demonstrated to
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disrupt the border between the ILM and vitreous body in macaque, resulting in an
increased transduction similar to the effect of pronase E on rodents (Yin et al., 2011).
Although the ILM of the rodent retina is relatively homogeneous, the thickness of the ILM
can also vary among different regions of the retina, given the fact that the AAV
transduction efficiency (represented by the mCherry expression level) was higher in the
peripheral area of the retina than that in the center and middle areas of the retina. My
results also demonstrated that the cell density in the center area of the retina was
increased after treatment with the middle concentration of plasmin, and the cell density in
the middle area of the retina was also increased after treatment with both the low and
middle concentrations of plasmin. However, the cell density in the peripheral area of the
retina was not influenced by either the low or middle concentration of plasmin. This
indicated that modest digestion of ILM may allow more AAV viral vectors to access the
retina and infect more retinal bipolar cells. Nevertheless, there was no improvement in
the expression level of AAV-meditated mCherry in the retina after intravitreal injection of
AAV2 virus and plasmin. Since the ILM is much thicker in primates and human than that
in rodents (Matsumoto et al., 1984), therefore, removal of the ILM in primates could play
a more important role in improving AAV transduction efficiency in the retina than removal
of the ILM in rodents. Further studies may need to be done in primate models in order to
better evaluate the effect of plasmin on improving AAV transduction efficiency in the retina
following intravitreal injection.
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CHAPTER 5: CONCLUSION AND FUTURE DIRECTIONS
Optogenetic therapy is one of the most promising developing therapies for vision
restoration. Targeting retinal bipolar cells with AAV viral vectors has been drawing
increasing interest. However, the AAV transduction efficiency in bipolar cells is low. In this
study, I tested my hypotheses that virus degradation during intracellular trafficking and
poor virus accessibility to bipolar cells are two main barriers for the efficient AAV
transduction to bipolar cells.
To test my first hypothesis, I evaluated the effect of three proteasome inhibitors,
doxorubicin, aclarubicin and MG132 on AAV-mediated transduction efficiency in retinal
bipolar cells in mice. My results show that doxorubicin, but not aclarubicin and MG132,
can improve the AAV transduction efficiency in retinal bipolar cells. Moreover, the way of
doxorubicin to improve AAV transduction efficiency is by increasing the number of cells
that are able to reach high transgene expression level, not by increasing the number of
cells transduced by AAV virus. The effective doses of doxorubicin after long-term
evaluation (3 months after treatment) are 200 – 500 μM. Since doxorubicin was reported
to induce neurotoxicity, I also evaluated the doxorubicin-induced toxicity in the mouse
retina. My results show that doxorubicin at a relative high concentration (300 – 500 μM)
could lead to cytotoxicity to retinal neurons in the long-term (3 months after treatment).
The cytotoxic effects include reducing the cell density of the GCL and the thickness of the
INL and IPL. Lens opacity was also observed in the mouse eyes. Dexrazoxane (Zinecard)
is a FDA-approved drug that has been used to reduce the doxorubicin-induced
cytotoxicity. Our results show that co-injection of dexrazoxane with doxorubicin can
mitigate the doxorubicin-induced cytotoxicity, while still maintaining the effect of
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doxorubicin. Under our experimental conditions, the optimal dose of doxorubicin if used
in combination with dexrazoxane is 200-300 μM, as it showed no long-term neurotoxicity
and the AAV-mediated transgene expression in bipolar cells was significantly improved.
With 500 μM doxorubicin however, the cell density of the GCL was still not brought back
to normal after co-administration of dexrazoxane, and the lens opacity was still observed
in the mouse eyes. This suggests that co-administration of dexrazoxane could not
completely abrogate the doxorubicin-induced cytotoxicity, especially when the dose of
doxorubicin was high.
To test my second hypothesis, I examined the effect of 3 different doses of plasmin
in improving AAV transduction efficiency in the retinal bipolar cells. My results show that
the density of the AAV-transduced retinal bipolar cells was increased in the center and
middle area of the retina following co-injection of AAV2 virus and middle and/or low
concentration of plasmin. However, there was no improvement in the AAV-mediated
transgene expression level in the retina after intravitreal injection of AAV2 virus and
plasmin. The relatively remarkable effect of plasmin in the center and middle areas of the
retina is probably due to the ILM is thicker in those areas. Since the ILM of the primates
and human is much thicker than that in rodents, removal of the ILM in primates might play
a more important role in improving AAV transduction efficiency in the retina than removal
of the ILM in rodents.
Further studies may need to be done in the following areas:
1. Improve the drug delivery protocol of the doxorubicin-dexrazoxane regimen. Multiple
combinations of drug delivery could be tested. For example, one-time doxorubicin
injection followed by multiple dexrazoxane injections at different time points, or
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dexrazoxane injection given prior to doxorubicin injection. More studies on the
pharmacodynamics and pharmacokinetics of doxorubicin and dexrazoxane in the eye
will help to develop an optimal protocol for drug delivery.
2. Evaluate the toxicity of plasmin in the retina. The hyperosmolarity of high dose plasmin
may cause transient retinal detachment. Digestion of the extracellular matrix by high
dose plasmin may also cause structural/functional abnormality of the retina.
3. Examine a combined regimen containing of doxorubicin, dexrazoxane, plasmin, and
a more potent viral vector such as 7m8. This combined regimen may further improve
the gene delivery efficiency in the retina. A therapeutic gene such as ChR2 can also
be tested with this regimen in a retinal degenerative disease model. Electrophysiology
and behavior studies can be done to evaluate the therapeutic gene delivery efficiency
of this combined regimen in disease models.
4. Evaluate the effect of plasmin in primate models. Intravitreal injection of AAV virus and
plasmin in primates might lead to a more prominent effect in improving AAV
transduction efficiency in the retina because of the thickness of the primate ILM.
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ABSTRACT
IMPROVING AAV TRANSDUCTION EFFICIENCY IN RETINAL BIPOLAR CELLS
FOR OPTOGENETIC VISION
by
SHENGJIE CUI
August 2018
Advisor: Dr. Zhuo-Hua Pan
Major: Anatomy and Cell Biology
Degree: Doctor of Philosophy
Recombinant adeno-associated virus (AAV) vectors are the most promising vehicles
for therapeutic gene delivery to the retina. We are developing AAV-mediated expression
of optogenetic tools in surviving inner retinal neurons as a potential strategy to restoring
vision after the death of photoreceptor cells in retinal degeneration. Targeting optogeneitc
tools, such as channelrhodopsin-2 (ChR2), to retinal bipolar cells (RBCs) is particularly
attractive. In particular, our lab has recently developed an optimized mGluR6 promoterbased virus vector that can mainly target ChR2 to rod bipolar cells. However, AAVmediated transduction efficiency in RBCs is relatively low. The transduction efficiency
could be affected by a number of factors, including the physical barrier of the retina and
proteasome degradation during intracellular trafficking. In this dissertation, I evaluated the
effect of proteasome inhibitors on improving AAV-mediated transduction efficiency in
retinal bipolar cells. My result indicated that doxorubicin, among other proteasome
inhibitors, is effective in improving AAV transduction efficiency in retinal bipolar cells in a
dose-dependent manner. I then evaluated doxorubicin-induced long-term toxicity to the
mouse retinas and lenses. Dexrazoxane was co-administered with doxorubicin to prevent
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its long-term toxicity. The optimal regimen for long-term use was found to be 200-300 μM
doxorubicin used in combination with dexrazoxane. I also examined the effect of plasmin
on improving the AAV-mediated transduction efficiency in retinal bipolar cells. My results
showed that plasmin did not improve the AAV transgene expression level in retinal bipolar
cells in mice. However, middle and/or low concentration of plasmin increased the number
of retinal bipolar cells that express mCherry transgene in the center and middle area of
the retina. The studies will help to develop useful tools in improving the AAV-mediated
transgene expression, potentially optogenetic light sensor expression, in retinal bipolar
cells, which may further contribute to new clinical applications.
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